P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (NCT04960579)

🧪 Interventions in This Study

• P-BCMA-ALLO1 CAR-T cells (BIOLOGICAL)
• Rimiducid (DRUG)
• Methotrexate (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• City of Hope — Goodyear, Arizona
• University of California San Diego — San Diego, California
• University of California San Francisco — San Francisco, California
• Emory University — Atlanta, Georgia
• Blood Marrow and Transplant Group of Georgia — Atlanta, Georgia
• City of Hope — Chicago, Illinois
• Advocate Aurora Health — Park Ridge, Illinois
• University of Iowa — Iowa City, Iowa
• University of Kansas Medical Center — Kansas City, Kansas
• University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
• Wayne State - Karmanos Cancer Institute — Detroit, Michigan
• Hackensack Meridian Health — Hackensack, New Jersey
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• Mount Sinai — New York, New York
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• University of Cincinnati — Cincinnati, Ohio
• Cleveland Clinic — Cleveland, Ohio
• University of Oklahoma, Health Sciences Center — Oklahoma City, Oklahoma
• University of Pennsylvania — Philadelphia, Pennsylvania
• Vanderbilt University Medical Center — Nashville, Tennessee
• Sarah Cannon Research Institute - St. David's South Austin Medical Center — Austin, Texas
• Houston Methodist Research Institute — Houston, Texas
• Sarah Cannon Research Institute - Methodist Healthcare — San Antonio, Texas

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.